GGrantIndex
← Leaderboards

The Mclean Hospital Corporation

Compare ↔
$20,660,783
Total funding
15
Grants

Funding over time

peak $9.5M · FY200825
$10M$7.5M$5M$2.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

DOD$20,660,783 · 15

By mechanism

$20,660,783 · 15

Investigators at The Mclean Hospital Corporation

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

Not enough data

Emerging Leaders

6–10 yrs in

Not enough data

All-Time

Most funded here, all years

Not enough data

Largest grants

THE PURPOSE OF THIS AGREEMENT IS TO FUND RESEARCH SUPPORTING THE DEFENSE ADVANCED RESEARCH PROJECTS AGENCY DARPA DEFENSE SCIENCES OFFICES DSO STRENGTHENING RESILIENT EMOTIONS AND NIMBLE COGNITION THROUGH ENGINEERING NEUROPLASTICITY STRENGTHEN PROGRAM. THIS EFFORT SHALL BE CARRIED OUT GENERALLY AS SET FORTH IN EXHIBIT B, RESEARCH DESCRIPTION DOCUMENT, DATED JUNE 27, 2023, AND IN THE RECIPIENTS REVISED PROPOSAL TITLED, NOVEL AND CONVENTIONAL INTERVENTIONS FOR COGNITIVE AND EMOTIONAL FLEXIBILITY IN PATIENT TRAUMA NOCICEPT, DATED JANUARY 23, 2023, COPIES OF WHICH ARE IN THE POSSESSION OF BOTH PARTIES.$7,839,429
· FY2025 · Defense Advanced Research Projects Agency
INTERNET BASED COGNITIVE BEHAVIORAL THERAPY EFFECTS ON DEPRESSIVE COGNITIONS AND BRAIN FUNCTION$1,646,035
· FY2012 · Department of Defense
ENCHANCING COGNITIVE REHABILIATION BY IGF2 ENERGY SUBSTRATE REPURPOSED SAFE PHARMACEUTICALS$1,422,000
· FY2015 · Department of Defense
ASSESSING THE IMPACT OF ACETYLCHOLINESTERASE (ACHE) INHIBITION ON COGNITION AND BRAIN NEUROCHEMISTRY$1,282,676
· FY2025 · Defense Threat Reduction Agency
MECHANISMS OF SPECIFIC LIPID-INDUCED DEGENERATION CAUSING NONMOTOR SYMPTOMS OF PARKINSON'S DISEASE. NEW AWARD.$1,237,507
· FY2020 · Department of the Army
MECHANISMS OF SPECIFIC LIPID-INDUCED DEGENERATION CAUSING NONMOTOR SYMPTOMS OF PARKINSON'S DISEASE. NEW AWARD.$1,162,491
· FY2020 · Department of the Army
DEVELOPMENT OF LEAD AGENTS FOR ALS TREATMENT IN PRECLINICAL MODEL SYSTEMS BASED ON DIFFERENTIAL GENE EXPRESSION OF IGF-II$1,082,703
· FY2008 · Department of the Army
NICOTINE EFFECTS ON THE IMPACT OF STRESS$799,781
· FY2012 · Department of Defense
EFFECTS OF BRIGHT LIGHT THERAPY OF SLEEP, COGNITION, BRAIN FUNCTION, AND NEUROCHEMISTRY IN MILD TRAUMATIC BRAIN INJURY$754,040
· FY2011 · Department of the Army
SEX DIFFERENCES IN THE ABILITY TO PREDICT AND TREAT OPIATE ABUSE$732,587
· FY2017 · Department of Defense
REGENERATIVE CELL THERAPY FOR PARKINSON¿¿S DISEASE AND NEURODEGENERATIVE CONDITIONS$674,612
· FY2011 · Department of the Army
AAV-MEDIATED INCLUSION FORMATION AS A NOVEL GENE THERAPY STRATEGY FOR ALS$554,354
· FY2011 · Department of the Army
THE NEUROBIOLOGICAL BASIS AND POTENTIAL OF MODIFICATION OF EMOTIONAL INTELLIGENCE THROUGH AFFECTIVE/BEHAVIORAL TRAINING$551,897
· FY2009 · Department of Defense
NICOTINE TO REDUCE THE PSYCHOLOGICAL EFFECTS OF STRESS$511,915
· FY2017 · Department of Defense
NONSTEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) RESPONSE AND CENTRAL SENSITIZATION OF PAIN IN WOMEN WITH DYSMENORRHEA$408,756
· FY2025 · Defense Health Agency